# Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas

> **NCT05182164** · PHASE2 · RECRUITING · sponsor: **Institut Bergonié** · enrollment: 119 (estimated)

## Conditions studied

- Soft Tissue Sarcoma Adult
- Advanced Soft-tissue Sarcoma
- Ewing Sarcoma
- Osteosarcoma
- Undifferentiated Pleomorphic Sarcoma

## Interventions

- **DRUG:** Association of pembrolizumab + cabozantinib

## Key facts

- **NCT ID:** NCT05182164
- **Lead sponsor:** Institut Bergonié
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-25
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 119 (ESTIMATED)
- **Last updated:** 2025-10-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05182164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05182164, "Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05182164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*